Categories: Health

NTG Nordic Transport Group A/S – H1 2025 Conference Call

 | Source: NTG Nordic Transport Group A/S

NTG Nordic Transport Group A/S – H1 2025 Conference Call

We expect to release the H1 2025 interim results of NTG Nordic Transport Group on the evening of August 11, 2025. A webcast and conference call will be held in the morning of August 12, 2025, at 10:00 am CET.

At the call, Group CEO Mathias Jensen-Vinstrup and Group CFO Christian D. Jakobsen will present the H1 2025 Interim Financial Report. The presentation will be followed by a Q&A session.

Date: August 12, 2025
Time: 10:00 am CET

To attend the conference call, please go to: Conference Call – NTG H1 2025 Interim Financial Report or Investors | NTG Nordic Transport Group.

If you wish to ask questions during the conference call, please register through this link: Conference Call Q&A – NTG H1 2025 Interim Financial Report.

We recommend participants to dial in 10 minutes prior to the scheduled start time.

Contacts

Investor Relations
Sebastian Rosborg, tel. +45 42 12 80 99, sebastian.rosborg@ntg.com

Best regards,
NTG Nordic Transport Group A/S

GlobeNews Wire

Recent Posts

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 06, 2026…

2 hours ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI,…

2 hours ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing…

2 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies

AlUla, Saudi Arabia, Feb. 7, 2026 /PRNewswire/ -- The second edition of the AlUla Conference…

2 hours ago

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…

2 hours ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

February 06, 2026 17:17 ET  | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Feb. 06,…

2 hours ago